| Literature DB >> 23242583 |
Shinichi Hasegawa1, Yuji Yamamoto, Masataka Taguri, Satoshi Morita, Tsutomu Sato, Roppei Yamada, Takashi Oshima, Norio Yukawa, Takaki Yoshikawa, Yasushi Rino, Toshio Imada, Munetaka Masuda.
Abstract
This randomized Phase II trial is being conducted to evaluate the impact of omentectomy for advanced gastric cancer on patient survival. The primary endpoint is the 3-year relapse-free survival rate and the secondary endpoints are 5-year overall survival, intraoperative blood loss, length of the operation and postoperative morbidity (especially postoperative ileus). The planned sample size is 250 patients (125 for complete removal of the omentum and 125 for preservation of the omentum) to determine whether omentum-preserving gastrectomy may be a candidate procedure for a Phase III trial in a randomized Phase II setting.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23242583 DOI： 10.1093/jjco/hys208
Source DB: PubMed Journal: Jpn J Clin Oncol ISSN： 0368-2811 Impact factor: 3.019